Search
Fibrinogen human
go.drugbank.com/drugs/DB09222ApprovedInvestigationalFibrinogen concentrate (human) is a hematological agent. It works by replacing a specific protein in the blood, fibrinogen (factor I), that helps with blood clotting. It is a soluble plasma glycoprotein with a molecular weight of about 3...
Mixtures: SAN. VE TİC. LTD., EVICEL® SELLANTE DE FIBRINA HUMANAProducts: VERASEAL SOLUTIONS FOR SEALANT, 80 mg/ml, 500 IU/ml, HAEMOCOMPLETTAN-P 1G IV ENJEKSİYONLUK/İNFÜZYONLUK ÇÖZELTİ TOZUTegafur
go.drugbank.com/drugs/DB09256ApprovedInvestigationalTegafur (INN, BAN, USAN) is a prodrug of [DB00544] (5-FU), an antineoplastic agent used as the treatment of various cancers such as advanced gastric and colorectal cancers. … When converted and bioactivated to 5-FU, the drug mediates an anticancer activity by inhibiting thymidylate synthase (TS) during the pyrimidine pathway involved in DNA synthesis. 5-FU is listed on the
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP1A2 SubstratesInternational brands: ESUEEW AN TXylose
go.drugbank.com/drugs/DB09419ApprovedWithdrawnThe dextrorotary form of xylose, D-xylose, refers usually to the endogenously occurring form of the sugar in living things. The levorotary form, L-xylose, can refer to the form that is synthesized. … D-Xylose is a sugar widely used as a diabetic sweetener in food and beverage. Xylose has also been used as a diagnostic agent to observe malabsorption.
Synonyms: D-Xylose, aldehydo-D-xyloseRibavirin
go.drugbank.com/drugs/DB00811ApprovedInvestigationalAdditionally, including ribavirin in the regimen can increase the risk of anemia. … Newer drugs developed as Hepatitis C viral infection treatments can be used to reduce or eliminate the use of ribavirin, which are associated with serious adverse effects.
Mixtures: Rebetron Ready To Use Solution (albumin(human)free) (6000000 Iu/ml and 200mg Capsules)Synonyms: 1-beta-D-Ribofuranosyl-1,2,4-triazole-3-carboxamide, 1-beta-D-Ribofuranosyl-1H-1,2,4-triazole-3-carboxamideVusolimogene oderparepvec
go.drugbank.com/drugs/DB23008ApprovedInvestigationalcells, causing tumor lysis and release of tumor and viral antigens, with the GALV-GP-R– glycoprotein enhancing direct tumor killing and GM-CSF promoting dendritic cell and monocyte activation to drive an … ] The FDA granted vusolimogene oderparepvec-wtpg accelerated approval on August 6, 2026, in combination with nivolumab for adults with unresectable advanced cutaneous melanoma that progressed on a PD
Molindone
go.drugbank.com/drugs/DB01618ApprovedMolindone has much lower affinity for D2 receptors than most antipsychotic agents and has a relatively low affinity for D1 receptors. … An indole derivative effective in schizophrenia and other psychoses and possibly useful in the treatment of the aggressive type of undersocialized conduct disorder.
Categories: Dopamine D2 Receptor AntagonistsGlecaprevir
go.drugbank.com/drugs/DB13879ApprovedInvestigationalIn cell cultures, the emergence of amino acid substitutions at NS3 resistance-associated positions A156 or D/Q168 in HCV genotype 1a, 2a or 3a replicons led to reduced susceptibility to glecaprevir [FDA … Mavyret is also indicated for HCV genotype 1-infected patients who have been previously treated with regimens either containing an NS5A inhibitor or an NS3/4A protease inhibitor, but not both [L940].
Categories: P-glycoprotein inhibitors, P-glycoprotein substratesPhenylpropanolamine
go.drugbank.com/drugs/DB00397ApprovedVet approvedWithdrawnCurrently, it is withdrawn from the market in Canada and the United States due to the risk for hemorrahgic strokes.
Mixtures: FLUTAMOL-P, FLUTAMOL - PSonrotoclax
go.drugbank.com/drugs/DB18753ApprovedInvestigational[L56193,A275521] Sonrotoclax was rationally designed as a BH3 mimetic with a shallow and broad interaction with the P2 pocket of BCL-2, achieved through a novel 7-azaspiro[3.5]nonane linker; this binding … Sonrotoclax is a selective, potent, small-molecule inhibitor of BCL-2, an antiapoptotic protein overexpressed in B-cell malignancies.
Categories: P-glycoprotein substrates, Cytochrome P-450 SubstratesVandetanib
go.drugbank.com/drugs/DB05294ApprovedInvestigationalVandetanib is an oral once-daily kinase inhibitor of tumour angiogenesis and tumour cell proliferation with the potential for use in a broad range of tumour types.
Categories: Cytochrome P-450 Substrates, P-glycoprotein inhibitors